Sava yahoo finance technical analysts expect either a

Technical analysts expect either a breakout or breakdown depending on incoming Phase 3 trial press releases. MultiPlan Corporation (NYSE:MPLN) is an American technology company that enables healthcare firms to manage their financial operations. Its third quarter earnings saw MultiPlan Corporation (NYSE:MPLN)'s revenue drop annually and net income turn into a loss as the firm cited future investments driving down its bottom line profit. However, developing drugs for this disease is a complex and challenging affair. Quite a few pharma and biotech players had earlier faced setbacks in developing an AD drug. Cassava Sciences, per SAVA Yahoo Finance charts, has tested resistance at $23 multiple times. RSI currently stands at 58, suggesting balanced momentum. Market watchers believe a breakout above $24 could invite new swing traders and short-covering interest.